Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Häfner R[au]:

Tuberculosis. Zumla A et al. N Engl J Med. (2013)

Curbing the tuberculosis and diabetes co-epidemic: strategies for the integration of clinical care and research. Bao J et al. Int J Tuberc Lung Dis. (2018)

[Pain syndrome of the musculoskeletal system in children and adolescents]. Höfel L et al. Z Rheumatol. (2016)

Search results

Items: 1 to 50 of 241

1.

Exploring the role of alignability effects in promoting uptake of energy-efficient technologies.

Hafner RJ, Elmes D, Read D.

J Exp Psychol Appl. 2019 Nov 14. doi: 10.1037/xap0000253. [Epub ahead of print]

PMID:
31724420
2.

FeNO Variability When Using Different Analyzers at the Joint ATS/ERS Guideline Cutoff.

Bushe C, Kamada A, Hafner R.

Respiration. 2019 Nov 6:1. doi: 10.1159/000503936. [Epub ahead of print] No abstract available.

3.

Persistence of the clinical effect of grass allergen peptide immunotherapy after the second and third grass pollen season.

Ellis AK, Frankish CW, Armstrong K, Steacy L, Tenn MW, Pawsey S, Hafner RP.

J Allergy Clin Immunol. 2019 Sep 27. pii: S0091-6749(19)31246-1. doi: 10.1016/j.jaci.2019.09.010. [Epub ahead of print]

PMID:
31568796
4.

Curbing the diabetes and tuberculosis co-epidemic: the potential role of China.

Bao J, Sha W, Zhang WH, Zhang T, Muldoon K, Hafner R.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):663-668. doi: 10.5588/ijtld.18.0323.

PMID:
31315697
5.

Mesothelial mobilization in the developing lung and heart differs in timing, quantity, and pathway dependency.

Lüdtke TH, Rudat C, Kurz J, Häfner R, Greulich F, Wojahn I, Aydoğdu N, Mamo TM, Kleppa MJ, Trowe MO, Bohnenpoll T, Taketo MM, Kispert A.

Am J Physiol Lung Cell Mol Physiol. 2019 May 1;316(5):L767-L783. doi: 10.1152/ajplung.00212.2018. Epub 2019 Jan 31.

PMID:
30702346
6.

Curbing the tuberculosis and diabetes co-epidemic: strategies for the integration of clinical care and research.

Bao J, Hafner R, Lin Y, Lin HH, Magee MJ.

Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1111-1112. doi: 10.5588/ijtld.18.0482. No abstract available.

PMID:
30236174
7.

Unusually Long-Lived Photocharges in Helical Organic Semiconductor Nanostructures.

Hafner RJ, Tian L, Brauer JC, Schmaltz T, Sienkiewicz A, Balog S, Flauraud V, Brugger J, Frauenrath H.

ACS Nano. 2018 Sep 25;12(9):9116-9125. doi: 10.1021/acsnano.8b03165. Epub 2018 Sep 5.

PMID:
30138559
8.

Tuberculous meningitis: a roadmap for advancing basic and translational research.

Jain SK, Tobin DM, Tucker EW, Venketaraman V, Ordonez AA, Jayashankar L, Siddiqi OK, Hammoud DA, Prasadarao NV, Sandor M, Hafner R, Fabry Z; NIH Tuberculous Meningitis Writing Group.

Nat Immunol. 2018 Jun;19(6):521-525. doi: 10.1038/s41590-018-0119-x. No abstract available.

9.

Combination of ofatumumab and fresh frozen plasma in hypocomplementemic systemic lupus erythematosus: a case report.

Speth F, Hinze C, Häfner R.

Lupus. 2018 Jul;27(8):1395-1396. doi: 10.1177/0961203318756289. Epub 2018 Feb 13. No abstract available.

PMID:
29439647
10.

Conducting high-quality tuberculosis clinical trials in China: opportunities and challenges.

Bao J, Hafner R.

Int J Tuberc Lung Dis. 2017 Nov 1;21(11):1094-1100. doi: 10.5588/ijtld.17.0105.

PMID:
29037289
11.

Implementation of an Integrated Care Learning Experience Within the Psychiatry Clerkship: Nutrition Education of Patients with Serious Mental Illness.

Chou S, Raml D, Hafner R, Baerentzen B, Hammer S.

Acad Psychiatry. 2018 Jun;42(3):410-414. doi: 10.1007/s40596-017-0780-7. Epub 2017 Aug 15. No abstract available.

PMID:
28812282
12.

Applying Precision Medicine and Immunotherapy Advances from Oncology to Host-Directed Therapies for Infectious Diseases.

Mahon RN, Hafner R.

Front Immunol. 2017 Jun 29;8:688. doi: 10.3389/fimmu.2017.00688. eCollection 2017.

13.

Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis.

Ellis AK, Frankish CW, O'Hehir RE, Armstrong K, Steacy L, Larché M, Hafner RP.

J Allergy Clin Immunol. 2017 Aug;140(2):486-496. doi: 10.1016/j.jaci.2016.11.043. Epub 2017 Feb 21.

PMID:
28236469
14.

Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination.

Jayashankar L, Hafner R.

Front Immunol. 2016 Dec 16;7:577. doi: 10.3389/fimmu.2016.00577. eCollection 2016. Review.

15.

Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis.

Chengalroyen MD, Beukes GM, Gordhan BG, Streicher EM, Churchyard G, Hafner R, Warren R, Otwombe K, Martinson N, Kana BD.

Am J Respir Crit Care Med. 2016 Dec 15;194(12):1532-1540.

16.

[Pain syndrome of the musculoskeletal system in children and adolescents].

Höfel L, Draheim N, Häfner R, Haas JP.

Z Rheumatol. 2016 Apr;75(3):292-302. doi: 10.1007/s00393-016-0061-y. Review. German.

PMID:
26892925
17.

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.

Brown AN, Drusano GL, Adams JR, Rodriquez JL, Jambunathan K, Baluya DL, Brown DL, Kwara A, Mirsalis JC, Hafner R, Louie A.

MBio. 2015 Nov 3;6(6):e01741-15. doi: 10.1128/mBio.01741-15.

19.

Fgfr2 is required for the expansion of the early adrenocortical primordium.

Häfner R, Bohnenpoll T, Rudat C, Schultheiss TM, Kispert A.

Mol Cell Endocrinol. 2015 Sep 15;413:168-77. doi: 10.1016/j.mce.2015.06.022. Epub 2015 Jun 30.

PMID:
26141512
20.

Towards early inclusion of children in tuberculosis drugs trials: a consensus statement.

Nachman S, Ahmed A, Amanullah F, Becerra MC, Botgros R, Brigden G, Browning R, Gardiner E, Hafner R, Hesseling A, How C, Jean-Philippe P, Lessem E, Makhene M, Mbelle N, Marais B, McIlleron H, McNeeley DF, Mendel C, Murray S, Navarro E, Anyalechi EG, Porcalla AR, Powell C, Powell M, Rigaud M, Rouzier V, Samson P, Schaaf HS, Shah S, Starke J, Swaminathan S, Wobudeya E, Worrell C.

Lancet Infect Dis. 2015 Jun;15(6):711-20. doi: 10.1016/S1473-3099(15)00007-9. Epub 2015 May 6. Review.

21.

Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.

Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW; ACTG A5311 Study Team.

Antimicrob Agents Chemother. 2015;59(6):3399-405. doi: 10.1128/AAC.05128-14. Epub 2015 Mar 30.

22.

Advancing host-directed therapy for tuberculosis.

Wallis RS, Hafner R.

Nat Rev Immunol. 2015 Apr;15(4):255-63. doi: 10.1038/nri3813. Epub 2015 Mar 13. Review.

PMID:
25765201
23.

The excess choice effect: The role of outcome valence and counterfactual thinking.

Hafner RJ, White MP, Handley SJ.

Br J Psychol. 2016 Feb;107(1):36-51. doi: 10.1111/bjop.12120. Epub 2015 Feb 5.

PMID:
25660197
24.

Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects.

Couroux P, Patel D, Armstrong K, Larché M, Hafner RP.

Clin Exp Allergy. 2015 May;45(5):974-981. doi: 10.1111/cea.12488.

PMID:
25600085
25.

[Limitations of medicine:diagnosis and therapy of <<inflammatory>> back pain].

Scharer V, Hafner R, Ciurea A, Henning L, Somoskovi A, Weber R, Fehr J.

Praxis (Bern 1994). 2014 Mar 12;103(6):337-40. Review. German.

PMID:
24712089
26.

Slowness and sparseness have diverging effects on complex cell learning.

Lies JP, Häfner RM, Bethge M.

PLoS Comput Biol. 2014 Mar 6;10(3):e1003468. doi: 10.1371/journal.pcbi.1003468. eCollection 2014 Mar.

27.

Drug-resistant tuberculosis: time for visionary political leadership.

Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M, Zumla A.

Lancet Infect Dis. 2013 Jun;13(6):529-39. doi: 10.1016/S1473-3099(13)70030-6. Epub 2013 Mar 24. Review.

28.

Tuberculosis.

Zumla A, Raviglione M, Hafner R, von Reyn CF.

N Engl J Med. 2013 Feb 21;368(8):745-55. doi: 10.1056/NEJMra1200894. Review. No abstract available.

PMID:
23425167
29.

Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.

Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larché M, Hafner RP.

J Allergy Clin Immunol. 2013 Jan;131(1):103-9.e1-7. doi: 10.1016/j.jaci.2012.07.028. Epub 2012 Sep 13.

30.

Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide.

Grosset J, Almeida D, Converse PJ, Tyagi S, Li SY, Ammerman NC, Pym AS, Wallengren K, Hafner R, Lalloo U, Swindells S, Bishai WR.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15001-5. doi: 10.1073/pnas.1203636109. Epub 2012 Aug 27.

31.

Total pubertal growth in patients with juvenile idiopathic arthritis treated with growth hormone: analysis of a single center.

Bechtold S, Beyerlein A, Ripperger P, Roeb J, Dalla Pozza R, Häfner R, Haas JP, Schmidt H.

Growth Horm IGF Res. 2012 Oct;22(5):180-5. doi: 10.1016/j.ghir.2012.07.002. Epub 2012 Jul 31.

PMID:
22854327
32.

TB and HIV Therapeutics: Pharmacology Research Priorities.

Dooley KE, Kim PS, Williams SD, Hafner R.

AIDS Res Treat. 2012;2012:874083. doi: 10.1155/2012/874083. Epub 2012 Jul 5.

33.

Detection and treatment of subclinical tuberculosis.

Robertson BD, Altmann D, Barry C, Bishai B, Cole S, Dick T, Duncan K, Dye C, Ehrt S, Esmail H, Flynn J, Hafner R, Handley G, Hanekom W, van Helden P, Kaplan G, Kaufmann SH, Kim P, Lienhardt C, Mizrahi V, Rubin E, Schnappinger D, Sherman D, Thole J, Vandal O, Walzl G, Warner D, Wilkinson R, Young D.

Tuberculosis (Edinb). 2012 Nov;92(6):447-52. doi: 10.1016/j.tube.2012.06.004. Epub 2012 Jul 21.

34.

[Definition, diagnosis and therapy of chronic widespread pain and so-called fibromyalgia syndrome in children and adolescents. Systematic literature review and guideline].

Zernikow B, Gerhold K, Bürk G, Häuser W, Hinze CH, Hospach T, Illhardt A, Mönkemöller K, Richter M, Schnöbel-Müller E, Häfner R; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften.

Schmerz. 2012 Jun;26(3):318-30. doi: 10.1007/s00482-012-1168-y. Review. German.

PMID:
22760465
35.

[Physiotherapy for juvenile idiopathic arthritis].

Spamer M, Georgi M, Häfner R, Händel H, König M, Haas JP.

Z Rheumatol. 2012 Jul;71(5):387-95. doi: 10.1007/s00393-011-0867-6. German.

PMID:
22732914
36.

Clinical research and development of tuberculosis diagnostics: moving from silos to synergy.

Nahid P, Kim PS, Evans CA, Alland D, Barer M, Diefenbach J, Ellner J, Hafner R, Hamilton CD, Iademarco MF, Ireton G, Kimerling ME, Lienhardt C, MacKenzie WR, Murray M, Perkins MD, Posey JE, Roberts T, Sizemore C, Stevens WS, Via L, Williams SD, Yew WW, Swindells S.

J Infect Dis. 2012 May 15;205 Suppl 2:S159-68. doi: 10.1093/infdis/jis194. Epub 2012 Apr 3. Review.

37.

Innovative trial designs are practical solutions for improving the treatment of tuberculosis.

Phillips PP, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, McHugh T, Pletschette M, Lienhardt C, Hafner R, Mgone C, Zumla A, Nunn AJ, Hoelscher M.

J Infect Dis. 2012 May 15;205 Suppl 2:S250-7. doi: 10.1093/infdis/jis041. Epub 2012 Mar 22.

PMID:
22448027
38.

New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.

Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jaramillo E, Hoelscher M, Zumla A, Gheuens J.

J Infect Dis. 2012 May 15;205 Suppl 2:S241-9. doi: 10.1093/infdis/jis034. Epub 2012 Mar 22. Review.

PMID:
22448022
39.

Viewpoint: Challenges and opportunities in tuberculosis research.

Kim PS, Makhene M, Sizemore C, Hafner R.

J Infect Dis. 2012 May 15;205 Suppl 2:S347-52. doi: 10.1093/infdis/jis190. Epub 2012 Mar 22. No abstract available.

40.

Eliminating tuberculosis and tuberculosis-HIV co-disease in the 21st century: key perspectives, controversies, unresolved issues, and needs.

Zumla A, Atun R, Maeurer M, Kim PS, Jean-Philippe P, Hafner R, Schito M.

J Infect Dis. 2012 May 15;205 Suppl 2:S141-6. doi: 10.1093/infdis/jir880. Epub 2012 Mar 22. No abstract available.

41.

Advancing the development of tuberculosis therapy.

Zumla A, Hafner R, Lienhardt C, Hoelscher M, Nunn A.

Nat Rev Drug Discov. 2012 Mar 1;11(3):171-2. doi: 10.1038/nrd3694.

PMID:
22378254
42.

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W; National Institutes of Health; Centers for Disease Control and Prevention.

Am J Respir Crit Care Med. 2011 Oct 15;184(8):972-9. doi: 10.1164/rccm.201105-0827WS.

43.

Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy.

Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, Buhot C, Verhoef A, Maillère B, Kay AB, Larché M.

J Allergy Clin Immunol. 2011 Jan;127(1):89-97, 97.e1-14. doi: 10.1016/j.jaci.2010.11.029.

PMID:
21211644
44.

Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial.

Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, Bica B, Campos L, Häfner R, Hofer M, Ozen S, Huemer C, Bae SC, Sztajnbok F, Arguedas O, Foeldvari I, Huppertz HI, Gamir ML, Magnusson B, Dressler F, Uziel Y, van Rossum MA, Hollingworth P, Cawkwell G, Martini A, Ruperto N; Pediatric Rheumatology International Trials Organisation (PRINTO).

Ann Rheum Dis. 2010 Aug;69(8):1479-83. doi: 10.1136/ard.2009.120840. Epub 2010 Jun 4.

PMID:
20525842
45.

Capture of endothelial progenitor cells by a bispecific protein/monoclonal antibody molecule induces reendothelialization of vascular lesions.

Langer HF, von der Ruhr JW, Daub K, Schoenberger T, Stellos K, May AE, Schnell H, Gauss A, Hafner R, Lang P, Schumm M, Bühring HJ, Klingel K, Conrad S, Schaller M, van Zandvoort M, Jung G, Dimmeler S, Skutella T, Gawaz M.

J Mol Med (Berl). 2010 Jul;88(7):687-99. doi: 10.1007/s00109-010-0614-5. Epub 2010 Apr 23.

PMID:
20414631
46.

Exposure to animals and risk of oligoarticular juvenile idiopathic arthritis: a multicenter case-control study.

Radon K, Windstetter D, Poluda D, Häfner R, Thomas S, Michels H, von Mutius E.

BMC Musculoskelet Disord. 2010 Apr 20;11:73. doi: 10.1186/1471-2474-11-73.

47.

Dynamics of body composition and bone in patients with juvenile idiopathic arthritis treated with growth hormone.

Bechtold S, Ripperger P, Dalla Pozza R, Roth J, Häfner R, Michels H, Schwarz HP.

J Clin Endocrinol Metab. 2010 Jan;95(1):178-85. doi: 10.1210/jc.2009-0979. Epub 2009 Oct 30.

PMID:
19880788
48.

Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

Tebas P, Zhang J, Hafner R, Tashima K, Shevitz A, Yarasheski K, Berzins B, Owens S, Forand J, Evans S, Murphy R.

J Antimicrob Chemother. 2009 May;63(5):998-1005. doi: 10.1093/jac/dkp071. Epub 2009 Mar 19.

49.

Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy.

Fischer M, Joos B, Niederöst B, Kaiser P, Hafner R, von Wyl V, Ackermann M, Weber R, Günthard HF.

Retrovirology. 2008 Nov 26;5:107. doi: 10.1186/1742-4690-5-107.

50.

[Juvenile fibromyalgia syndrome].

Michels H, Gerhold K, Häfner R, Häuser W, Illhardt A, Mönkemöller K, Richter M, Schuchmann L.

Schmerz. 2008 Jun;22(3):339-48. doi: 10.1007/s00482-008-0679-z. German.

PMID:
18470540

Supplemental Content

Loading ...
Support Center